000163926 001__ 163926
000163926 005__ 20240229123201.0
000163926 0247_ $$2doi$$a10.1002/cam4.3476
000163926 0247_ $$2pmid$$apmid:33022889
000163926 0247_ $$2altmetric$$aaltmetric:91919799
000163926 037__ $$aDKFZ-2020-02150
000163926 041__ $$aeng
000163926 082__ $$a610
000163926 1001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b0$$eFirst author$$udkfz
000163926 245__ $$aAge-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls.
000163926 260__ $$aHoboken, NJ$$bWiley$$c2020
000163926 3367_ $$2DRIVER$$aarticle
000163926 3367_ $$2DataCite$$aOutput Types/Journal article
000163926 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609155826_26352
000163926 3367_ $$2BibTeX$$aARTICLE
000163926 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163926 3367_ $$00$$2EndNote$$aJournal Article
000163926 500__ $$a#EA:C071#LA:C071#2020 Nov;9(22):8713-8721
000163926 520__ $$aDepression is more prevalent in breast cancer (BC) survivors than in the general population. However, little is known about depression in long-term survivors. Study objectives were: (1) to compare the age-specific prevalence of depressive symptoms (a) in BC survivors vs female population controls, (b) in disease-free BC survivors vs BC survivors with self-reported recurrence vs controls, and (2) to explore determinants of depression in BC survivors.About 3010 BC survivors (stage I-III, 5-16 years post-diagnosis), and 1005 population controls were recruited in German multi-regional population-based studies. Depression was assessed by the Geriatric Depression Scale-15. Prevalence of mild/severe and severe depression only were estimated via logistic regression, controlling for age and education. Multinomial logistic regression was used to explore determinants of mild and severe depression.Compared with population controls, BC survivors were more likely to report mild/severe depression (30.4% vs 23.8%, p = .0003), adjusted for age and education. At all age groups <80 years, prevalence of both mild/severe and severe depression only was significantly higher in BC survivors, while BC survivors ≥80 years reported severe depression less frequently than controls. BC survivors with recurrence reported significantly higher prevalence of mild/severe depression than disease-free survivors and controls, but prevalence in disease-free survivors and controls was comparable. Age, income, living independently, recurrence, and BMI were significant determinants of mild depression in BC survivors. Age, education, employment, income, recurrence, and BMI were significant determinants of severe depression.Long-term BC survivors <80 years report significantly higher prevalence of depressive symptoms than controls, which might be explained by recurrence and individual factors. The findings suggest that depression in BC survivors is common, and even more after BC recurrence. Clinicians should routinize screening and normalize referral to psychological care.
000163926 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163926 588__ $$aDataset connected to CrossRef, PubMed,
000163926 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b1$$udkfz
000163926 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000163926 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b3$$udkfz
000163926 7001_ $$aBertram, Heike$$b4
000163926 7001_ $$00000-0003-4195-5236$$aEberle, Andrea$$b5
000163926 7001_ $$aHolleczek, Bernd$$b6
000163926 7001_ $$aPritzkuleit, Ron$$b7
000163926 7001_ $$00000-0002-5909-9936$$aWaldmann, Annika$$b8
000163926 7001_ $$00000-0002-0743-6128$$aZeissig, Sylke R$$b9
000163926 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000163926 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b11$$eLast author$$udkfz
000163926 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.3476$$gp. cam4.3476$$n22$$p8713-8721$$tCancer medicine$$v9$$x2045-7634$$y2020
000163926 909CO $$ooai:inrepo02.dkfz.de:163926$$pVDB
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000163926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000163926 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163926 9141_ $$y2020
000163926 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2018$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-01-09
000163926 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-09
000163926 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-09
000163926 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000163926 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000163926 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000163926 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000163926 980__ $$ajournal
000163926 980__ $$aVDB
000163926 980__ $$aI:(DE-He78)C071-20160331
000163926 980__ $$aI:(DE-He78)C070-20160331
000163926 980__ $$aI:(DE-He78)C120-20160331
000163926 980__ $$aI:(DE-He78)HD01-20160331
000163926 980__ $$aUNRESTRICTED